Biotech Stocks for a Possible Year-End Rally [View article]
While I like the Biotech sector, and there are many worthy companies to purchase, with real potential big gains, in my opinion, Thanksgiving week should be slow. More sales than buys too. However, more signals point to a fairly large sell off beginning the first week of December. I believe in the best interest of shareholders, it would be wiser to wait until the third week of January to check the pulse of the Dow, before investing any money into any company. RISK/REWARD TO DANGEROUS FOR THE MONTH OF DECEMBER, WITH THIS PUMPED UP DOW!
RNA Interference Stocks: Invest At Your Own Risk [View article]
MAY 27TH, 2009 DEAR MR.SCHULMAN, BEFORE YOU GO ON VACATION AGAIN, HOW ABOUT YOUR PERSPECTIVE ON 'MRNA' FORMERELY 'NSTK' IN 8 WEEKS THE TWO PARTNERSHIP DEALS CAUSED A SHAREHOLDERS FEVER DRIVING THE STOCK PRICE FROM HIGH $.20 CENT RANGE TO $1.99. AFTER A MORE THAN 600% RUN UP, IT IS SLOWLY GOING DOWN, CLOSING TODAY AT $1.50. PERSONALLY, I BELIEVE IT BELONG BELOW $.50 CENTS. THEY ARE A PRE-CLINICAL STAGE COMPANY, AND JUST REGAINED COMPLIANCE BEING OVER ONE DOLLAR, BUT I STRONLY BELIEVE IT IS HEADING BACK WHERE IT BELONGS, AROUND $.50 CENTS TO MAYBE LOW $.70 CENT RANGE. CAN YOU PLEASE SOBER THE SHAREHOLDERS UP BEFORE YOU START YOUR LONG WALKS ON THE BEACH?
RNA Interference Stocks: Invest At Your Own Risk [View article]
MRNA-DEC.11TH NOW $.25 CENTS QUITE A TASK MR.SHULMAN ACHIEVED, DON'T YOU THINK? I HAVE BEEN ACCURATE ON THIS STOCK GOING ON 18 MONTHS TO DATE. WITHOUT A PARTNER SOON, THEY HAVE ABOUT 9MONTHS OF CASH ON HAND TO PAY EXPENSES AND THEN THAT'S IT. FINDING A PARTNER DURING A SEVERE CREDIT CRISIS AND UNSTABLE STOCK MARKET ISN'T GOING TO BE EASY WHILE THE CLOCK IS TICKING. SO WHEN YOU TOLD INVESTORS TO STAY AWAY FROM RNAI STOCKS, YOU TOO, COULDN'T HAVE BEEN MORE RIGHT ABOUT THE SUBJECT. ENJOY YOUR NEXT VACATION! HAPPY HOLIDAYS!
'When There's Blood in the Streets', Buy Biotech Stocks [View article]
Ohad Hammer, I admire your guts and position. Jim Cramer has now done a 360 and advising people to sell everything, after hitting the buy,buy,buy bottom for years, and you are informing others about history and for people to consider biotechs now. But part of history is the depression to consider. At a time when global markets are plunging, I do not believe this is safe advice to publish. We are in a beginning stages of a global depression which will take years to possibly recuperate from. So investors are better off for now to hold onto their money, and use it for survival. It is bad out there and we are making new history Mr.Hammer.
Alnylam Pharmaceuticals: A Falling Star [View article]
FANTASTIC AND SOBERING ARTICLE MR. HUCKMAN. TO MANY COMPANIES MAKE CHRONIC NEWS RELEASES OVER AGREEMENTS, EXCLUSIVES AND OVER HYPE THE STOCK CREATING ENTHUSIASM AS YOU SO STATED. BUT THAT ONLY LEAVES THE SHAREHOLDERS HOLDING THE BAG FOR MANY YEARS TO COME. IF MR. ALSENAS, SENIOR ANALYST, IS TELLING CLIENTS THAT 'ALYNAM' MAY NEVER DEVELOP A PRODUCT REGARDING 'RNAI', THEN COMPANIES WHO ARE FAR BEHIND ALYNAM CURRENT PROGRESS, REALISTICALLY HAS THE SAME SCENARIO PROGNOSIS. CASE IN POINT THE NEW COMPANY 'MRNA'(MDRNA INC). AS MR. ALSENAS STATS RNAI FAD IS GETTING SHAREHOLDERS TOO EXCITED AND A RNAI PRODUCT IS YEARS AWAY.
RNA Interference Stocks: Invest At Your Own Risk [View article]
OH BY THE WAY THE STOCK WENT FROM $18 DOLLARS TO $1.16. AND THEIR LATEST CONFERENCE CALL WITH THEIR OWN RESEARCH FIRMS THAT FOLLOW NSTK WENT WELL LIKE A PLAY ON BROADWAY! ON COURSE FOR NEW LOWS, AND $1.00 BID BY AUGUST 21ST. I STILL WOULD LIKE TO KNOW WHY THEIR CHIEF FINANCIAL OFFICER RESIGNED? SOME RECORD TO DATE & SOME STATISTICS
RNA Interference Stocks: Invest At Your Own Risk [View article]
MR.SHULMAN HAS AVOIDED THE QUESTION GOING ON 12 MONTHS SOON. SO I'LL GIVE YOU MY VIEWPOINT THAT HASN'T CHANGED FOR 1 YEAR NOW. THEY TOUT THIS STOCK TO DEATH AND MURPHY'S LAW ALWAYS IS EVER PRESENT. PARTNERSHIPS BREAK UPS ARE COMMON, DILUTION IS CHRONIC, REVENUE IS DOWN, EXPENSES ARE UP, NSTK ACCOUNTS ISSUED A WARNING OF CONTINUANCE LETTER, AND AFTER 24 YEARS THE COMPANY HAS ACCOMPLISHED NOTHING. THE BURN RATE SHOULD BALANCE THEIR RNAI RESEARCH TO A SCREECHING HALT. NOW MR.SCHULMAN YOU CAN START GOING ON YOUR VACATIONS LIKE LAST SUMMER AND ENJOY THE BEACH.
RNA Interference Stocks: Invest At Your Own Risk [View article]
Mr.Shulman, Still waiting for your perspective regarding 'nstk' since you promised last Friday, July 27th, 2007. Your viewpoint is needed please! Your article July 16th was crisp and informative.(RNAI) But 17 Touts by Jimmy Cramer is a bit much on nstk based on your article, don't you think? I look forward to your intelligent response! JIMMY T
Biotech Stocks for a Possible Year-End Rally [View article]
week should be slow. More sales than buys too. However, more signals point to a fairly large sell off beginning the first week of December. I believe in the best interest of shareholders, it would be wiser to wait until the third week of January to check the pulse of the Dow, before investing any money into any company.
RISK/REWARD TO DANGEROUS FOR THE MONTH OF DECEMBER, WITH THIS PUMPED UP DOW!
RNA Interference Stocks: Invest At Your Own Risk [View article]
DEAR MR.SCHULMAN, BEFORE YOU GO ON VACATION AGAIN, HOW ABOUT YOUR PERSPECTIVE ON 'MRNA' FORMERELY 'NSTK'
IN 8 WEEKS THE TWO PARTNERSHIP DEALS
CAUSED A SHAREHOLDERS FEVER DRIVING THE STOCK PRICE FROM HIGH $.20 CENT RANGE TO $1.99. AFTER A MORE THAN 600% RUN UP, IT IS SLOWLY GOING DOWN,
CLOSING TODAY AT $1.50. PERSONALLY, I BELIEVE IT BELONG BELOW $.50 CENTS.
THEY ARE A PRE-CLINICAL STAGE COMPANY, AND JUST REGAINED COMPLIANCE BEING OVER ONE DOLLAR, BUT I STRONLY BELIEVE IT IS HEADING BACK WHERE IT BELONGS, AROUND $.50 CENTS TO MAYBE LOW $.70 CENT RANGE.
CAN YOU PLEASE SOBER THE SHAREHOLDERS UP BEFORE YOU START YOUR LONG WALKS ON THE BEACH?
RNA Interference Stocks: Invest At Your Own Risk [View article]
QUITE A TASK MR.SHULMAN ACHIEVED, DON'T YOU THINK?
I HAVE BEEN ACCURATE ON THIS STOCK GOING ON 18 MONTHS TO DATE. WITHOUT A PARTNER SOON, THEY HAVE ABOUT 9MONTHS OF CASH ON HAND TO PAY EXPENSES AND THEN THAT'S IT.
FINDING A PARTNER DURING A SEVERE CREDIT CRISIS AND UNSTABLE STOCK MARKET ISN'T GOING TO BE EASY WHILE THE CLOCK IS TICKING.
SO WHEN YOU TOLD INVESTORS TO STAY AWAY FROM RNAI STOCKS, YOU TOO, COULDN'T HAVE BEEN MORE RIGHT ABOUT THE SUBJECT.
ENJOY YOUR NEXT VACATION!
HAPPY HOLIDAYS!
'When There's Blood in the Streets', Buy Biotech Stocks [View article]
Jim Cramer has now done a 360 and advising people to sell everything, after hitting the buy,buy,buy bottom for years, and you are informing others about history and for people to consider biotechs now. But part of history is the depression to consider. At a time when global markets are plunging, I do not believe this is safe advice to publish. We are in a beginning stages of a global depression which will take years to possibly recuperate from. So investors are better off for now to hold onto their money, and use it for survival. It is bad out there and we are making new history Mr.Hammer.
Alnylam Pharmaceuticals: A Falling Star [View article]
TO MANY COMPANIES MAKE CHRONIC NEWS RELEASES OVER AGREEMENTS, EXCLUSIVES AND OVER HYPE THE STOCK CREATING ENTHUSIASM AS YOU SO STATED. BUT THAT ONLY LEAVES THE SHAREHOLDERS HOLDING THE BAG FOR MANY YEARS TO COME. IF MR. ALSENAS, SENIOR ANALYST, IS TELLING CLIENTS THAT 'ALYNAM' MAY NEVER DEVELOP A PRODUCT REGARDING 'RNAI', THEN COMPANIES WHO ARE FAR BEHIND ALYNAM CURRENT PROGRESS, REALISTICALLY HAS THE SAME SCENARIO PROGNOSIS.
CASE IN POINT THE NEW COMPANY 'MRNA'(MDRNA INC).
AS MR. ALSENAS STATS RNAI FAD IS GETTING SHAREHOLDERS TOO EXCITED AND A RNAI PRODUCT IS YEARS AWAY.
RNA Interference Stocks: Invest At Your Own Risk [View article]
AND THEIR LATEST CONFERENCE CALL WITH THEIR OWN RESEARCH FIRMS THAT FOLLOW NSTK WENT WELL LIKE A PLAY ON BROADWAY!
ON COURSE FOR NEW LOWS, AND $1.00 BID BY AUGUST 21ST.
I STILL WOULD LIKE TO KNOW WHY THEIR CHIEF FINANCIAL OFFICER RESIGNED? SOME RECORD TO DATE & SOME STATISTICS
RNA Interference Stocks: Invest At Your Own Risk [View article]
RNA Interference Stocks: Invest At Your Own Risk [View article]
Still waiting for your perspective regarding 'nstk' since you promised last Friday, July 27th, 2007.
Your viewpoint is needed please!
Your article July 16th was crisp and informative.(RNAI)
But 17 Touts by Jimmy Cramer is a bit much on nstk based on your article, don't you think?
I look forward to your intelligent response!
JIMMY T